Notice for garadacimab (CSL Behring Australia Pty Ltd)
Active ingredients
garadacimab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
solution for injection
Indication
For the routine prevention of hereditary angioedema (HAE) attacks
Therapeutic area
Immunology